10 Aug 2017

Nicola Sturgeon: interview at the official opening of REPROCELL's Centre for Predictive Drug Discovery (YouTube video)

First Minister Nicola Sturgeon officially opened the new European headquarters of a life sciences company which is set to generate 15 new jobs and safeguard a further three following new investment.

13 May 2016

Latest Proteon and Biopta publication demonstrates Proteon's Vonapanitase effects in human cephalic veins

Proteon Therapeutics Inc., a collaborator of Biopta, today announced publication of additional nonclinical data on Vonapanitase, an investigational drug under development to improve Arteriovenous Fistula (AVF) maturation and patency in chronic kidney disease patients.

21 Apr 2016

Proteon and Biopta publication shows promising nonclinical results on Proteon's Vonapanitase

Proteon Therapeutics Inc. a collaborator of Biopta, today announced publication of additional nonclinical data on investigational drug vonapanitase in peripheral artery disease (PAD).

25 Nov 2015

Biopta to be acquired by Japanese stem cell company ReproCELL

Biopta is to be acquired by the stem cell and regenerative medicine company ReproCELL. The deal will help Biopta to expands its range of drug discovery services based on human fresh tissues.

1 2 3 4 >>

REPROCELL Chooses Science Exchange as the Preferred Partner to Increase Accessibility of its Predictive Drug Discovery Services


PALO ALTO, CA, November 8, 2017 – Science Exchange, the world’s leading and most secure enterprise platform for outsourced research services and procurement of human biospecimens, announced today that REPROCELL has selected the Science Exchange platform as the primary marketplace to offer access to its predictive drug discovery assays for the biopharma research community.


With REPROCELL as one of Science Exchange’s qualified service providers, researchers now have access to a diverse range of preclinical assay services using fresh human tissues, stem cells, and 3D models which offer the biopharma industry novel tools for investigating the safety and efficacy of new drug candidates early in the drug discovery process.


In addition, researchers are empowered to focus on innovation, while Science Exchange takes on the role of supporting the identification of new service providers such as REPROCELL, managing a secure contracting process, and delivering analytics to track performance and report process improvement.


“Our predictive drug discovery services using fresh human tissues, stem cells and 3D models are instrumental for researchers in the biopharma industry in ensuring the safety and efficacy of drug candidates in early stage development and mitigating the risk of unpredicted findings at a later stage,” said David Bunton, Ph.D., CEO of REPROCELL. “Our partnership with Science Exchange will enable researchers from all over the world to access our assay services while gaining the operational and service support that Science Exchange is known for in the scientific community.”


“The Science Exchange platform allows global biopharma researchers to source and secure research products and services in a highly compliant manner from a global network of 2,500+ commercial and academic research service providers,” said Elizabeth Iorns, Ph.D., co-founder and CEO of Science Exchange. “We are proud to add REPROCELL, a company well-known for its innovative stem cell technologies, preclinical assay services, and extensive repository of human tissue samples, to our network of qualified service providers – giving researchers easy access to powerful tools for new drug candidates’ investigation via the Science Exchange platform.”



REPROCELL Inc. was established in 2003 with the goal of contributing to people’s health and welfare through development of cutting-edge stem cell technologies, and has further diversified its unique portfolio to include predictive drug discovery services, as well as a global biorepository of human biospecimens and prospective collections which are instrumental for scientists researching disease areas including autoimmune, inflammatory, rheumatology, urology, and oncology. REPROCELL has an extensive network of more than 600,000 human tissue, serum, DNA and RNA samples from over 120,000 patients, spanning four continents. For more information, visit Follow the company on Twitter @REPROCELL_group.


About Science Exchange

Science Exchange is the world’s leading and most secure platform for outsourced research, providing an efficient procure-to-pay platform for ordering 6,000+ services from a network of more than 2,500 qualified scientific service providers, all with pre-established contracts in place that protect client intellectual property and confidentiality. The platform increases access to innovation and improves productivity, freeing scientists from administrative tasks and delays associated with sourcing, establishing and managing service provider contracts. Additionally, the Science Exchange enterprise program enables large R&D organizations to consolidate research outsourcing spend into a single strategic relationship, driving efficiency, improving transparency and oversight, and delivering cost savings. Since being founded in 2011, Science Exchange has raised more than $58 million from Norwest Venture Partners, Maverick Capital Ventures, Union Square Ventures, Collaborative Fund, Index Ventures, OATV, the YC Continuity Fund, and others. For more information, visit Follow the company on Twitter @ScienceExchange.

Visit REPROCELL at the “North East England Life Science Showcase” in Cambridge, MA (USA) on November 30, 2017


For life scientists in the USA, the North East England Life Science Showcase will be held on Thursday, November 30th, 2017 at the Boston Mariott Hotel in Cambridge, MA.


View the program and sign up here.


The orgainzer of the North East England Life Science Showcase, Prof. Anne Dickinson, Director of Alcyomics, will be giving a showcase presentation titled In vitro pre-clinical testing for predicting adverse immune reactions. Alcyomics’ pre-clinical Skimune®3D service uses REPROCELL’s Alvetex in its non-artificial human skin explants for safety and efficacy assessment of novel compounds and drugs.


Also included in the event program is a showcase presentation by REPROCELL’s Senior Technical Product Manager, Robert Annand, PhD. Dr Annand’s presentation on Human Tissue and 3D-Cell based Models for Drug Discovery will showcase REPROCELL’s pre-clinical contract research organization provides unique custom pharmacology assay services using freshly-sourced human tissues and 3D tissue models.


REPROCELL Europe Ltd.’s operations are based in North East England and in nearby Scotland. Our CSO, Prof. Stefan Przyborski, is also Professor of Cell Technology at Durham University (in North East England). Our CEO, Dr David Bunton, an expert in vascular pharmacology, was co-founder of Biopta (now REPROCELL Europe’s Center for Predictive Drug Discovery in Glasgow, Scotland) which specializes in drug discovery contract research using ethically sourced live human tissue from a network of hospitals.


The event is free to attend. View the program and sign up here. Please register by Friday, November 17th.

Live chat by BoldChat